Moderate Ischemia, Stable Symptoms: Medical Therapy or the Cath Lab First
A single patient whose symptoms are manageable enough that either path — a procedure or a better medication regimen — could plausibly be called sufficient. The disagreement is about which one gets tried, and proven, first.
C.W., a 66-year-old woman, took up watercolor painting three years ago, not long after she retired from three decades at the public library, and now sells small landscape pieces most Saturdays at the farmers market a few blocks from her house. Her hypertension has been well controlled on a single agent for over a decade, and osteoarthritis in both knees has quietly limited how far she walks comfortably, a detail that matters as much for reading her recent stress test as for anything else in her chart. Over the past several months she has noticed intermittent chest discomfort with exertion — carrying her painting supplies to the market, mostly — that has responded well to rest and hasn't stopped her from doing much of anything she wants to do.
Stress imaging shows a moderate, reproducible area of inducible ischemia, and angiography confirms a significant stenosis suitable for either percutaneous intervention or continued medical management. Her presentation sits close to the population ISCHEMIA actually enrolled — stable disease, moderate-to-severe ischemia on functional testing, symptoms manageable on medical therapy — and that trial found no significant difference in its composite of cardiovascular death, myocardial infarction, resuscitated cardiac arrest, or hospitalization for unstable angina or heart failure, between an initial invasive strategy and a conservative one built around optimized medical therapy. What ISCHEMIA did show, in patients who had angina at baseline, was a meaningful improvement in symptom-related quality of life with the invasive strategy — a real benefit, just not the mortality or infarction benefit that revascularization is sometimes assumed to carry by default.
Which one gets tried first
She has real anginal symptoms, and ISCHEMIA itself showed a meaningful quality-of-life benefit from revascularization in patients who had angina at baseline, even though the trial didn't show a mortality or infarction advantage. She's not asymptomatic — carrying her painting supplies triggers real chest discomfort — and I don't think we should undersell the value of actually relieving that just because the trial's primary endpoint came back neutral.
The primary endpoint being neutral is the headline result for a reason — it's the outcome that actually matters most, death and infarction, and revascularization didn't move it. Her symptoms right now aren't stopping her from doing the things she wants to do; she's still walking to the farmers market and setting up her table most Saturdays. I'd optimize her medical therapy first — a beta-blocker or nitrate added to what she's already on — before exposing her to a procedure whose main proven benefit here is symptomatic, when we haven't yet tried the symptomatic-benefit medical option.
If we optimize medical therapy and her symptoms improve, we've gotten the same quality-of-life benefit without the procedure. If they don't improve, we haven't lost anything — the angiographic anatomy suitable for PCI today is still suitable for PCI in six weeks.
One thing worth naming before either path gets called the obvious first step: her knee osteoarthritis limits how far she walks day to day, which means her current level of "well-controlled" symptoms may partly reflect that she rarely pushes herself hard enough to provoke more. That doesn't settle the argument, but it does mean we should optimize medical therapy with a real anti-anginal trial — not just her current regimen left unchanged — and set an actual symptom-based threshold for revisiting revascularization, rather than assuming her current comfort proves the medical strategy is already working as well as it could.
Beta-blocker added and titrated over several weeks with a structured symptom diary; aspirin confirmed and the statin intensified toward an LDL below 70 mg/dL, since "optimized medical therapy" has to actually be optimized for the comparison to mean anything.
The trial was framed this way because her knee-limited baseline activity made "well controlled" hard to fully trust without an actual medical-therapy trial. PCI was deferred but not ruled out, with an explicit plan to revisit if symptoms persist despite optimized medical therapy.